Coagulation Defects

2008 ◽  
pp. 61-96
Author(s):  
Elizabeth A. Letsky
Keyword(s):  
Coagulation Defects

Turnover and Distribution of 131Iodine-Labelled Human Fibrinogen

1964 ◽  
Vol 11 (02) ◽  
pp. 404-422 ◽  
Author(s):  
Annemarie Amris ◽  
C. J Amris
Keyword(s):  
Body Weight ◽  
Cancer Patient ◽  
Distribution Ratio ◽  
Half Life ◽  
Fibrinolytic Activity ◽  
The Other ◽  
Turnover Rates ◽  
Human Fibrinogen ◽  
Coagulation Defects ◽  
Fractional Turnover

Summary14 patients (5 diabetics with arteriosclerotic complications, 4 patients with thrombo-embolic disease, 4 with cirrhosis, coagulation defects and increased fibrinolytic activity, and 1 cancer patient) and 3 control patients were subjected to turnover studies with 13iodine labelled human fibrinogen.Half-life times in the control patients were found to be 4 days, the fractional turnover rates 19–23 per cent, of intravascular fibrinogen per day, and the absolute turnover 0.02 to 0.06 gm per day per kg. body weight. The other patient’s half-life times and turnover rates varied considerably from 0.9–5.5 days, 13–160 per cent, per day of intravascular fibrinogen and 0.02–0.4 gm per day per kg. body weight respectively.As fibrinogen unlike other proteins subjected to turnover studies, is converted to fibrin, it is not possible to measure the true intra-extravascular distribution ratio of fibrinogen. But intravascular fibrinogen could be approximated to constitute 68–99 per cent, of the total fibrinogen. There is justification in believing that fibrinogen is degradated through a continuous coagulation in equilibrium with fibrinolysis, and that the organism contains a greater mass of fibrin, the “fibrin pool”. Considerations of the turnover mechanism can however only be hypothetical.

The Effect of Dextran of Various Molecular Weight on the Coagulation in Dogs

1961 ◽  
Vol 06 (01) ◽  
pp. 015-024 ◽  
Author(s):  
Sven Erik Bergentz ◽  
Oddvar Eiken ◽  
Inga Marie Nilsson
Keyword(s):  
Molecular Weight ◽  
Body Weight ◽  
High Molecular Weight ◽  
Bleeding Time ◽  
Factor Vii ◽  
Low Molecular Weight ◽  
Factor V ◽  
Coagulation Mechanism ◽  
Coagulation Defects

Summary1. Infusions of low molecular weight dextran (Mw = 42 000) to dogs in doses of 1—1.5 g per kg body weight did not produce any significant changes in the coagulation mechanism.2. Infusions of high molecular weight dextran (Mw = 1 000 000) to dogs in doses of 1—1.5 g per kg body weight produced severe defects in the coagulation mechanism, namely prolongation of bleeding time and coagulation time, thrombocytopenia, pathological prothrombin consumption, decrease of fibrinogen, prothrombin and factor VII, factor V and AHG.3. Heparin treatment of the dogs was found to prevent the decrease of fibrinogen, prothrombin and factor VII, and factor V otherwise occurring after injection of high molecular weight dextran. Thrombocytopenia was not prevented.4. In in vitro experiments an interaction between fibrinogen and dextran of high and low molecular weight was found to take place in systems comprising pure fibrinogen. No such interaction occurred in the presence of plasma.5. It is concluded that the coagulation defects induced by infusions of high molecular weight dextran are due to intravascular coagulation.

Bleeding Time in Rats: A Comparison of Different Experimental Conditions

1982 ◽  
Vol 48 (01) ◽  
pp. 108-111 ◽  
Author(s):  
Elisabetta Dejana ◽  
Silvia Villa ◽  
Giovanni de Gaetano
Keyword(s):  
Platelet Function ◽  
Bleeding Time ◽  
Platelet Dysfunction ◽  
Experimental Conditions ◽  
Platelet Number ◽  
Coagulation Defects ◽  
Tail Tip ◽  
And Function ◽  
Storage Pool Disease ◽  
Type Of Anaesthesia

SummaryThe tail bleeding time (BT) in rats definitely varies according to the method applied. Of the various variables that may influence BT, we have evaluated the position (horizontal or vertical) of the tail, the environment (air or saline), the temperature (4°, 23° or 37° C) and the type of anaesthesia. Transection of the tail tip cannot be used to screen drugs active on platelet function since it is sensitive to coagulation defects. Template BT in contrast is not modified by heparin and is sensitive to defects of platelet number and function (“storage pool disease”, dipyridamole-like drugs, exogenous prostacyclin). In contrast the test fails to detect aspirin-induced platelet dysfunction. The evidence reported indicates that thromboxane A2-prostacyclin balance is not a factor regulating BT. Aspirin treatment however may be a precipitating factor when associated with other abnormalities of platelet function.Template BT is a valid screening test for platelet disorders and for antiplatelet drugs.

COAGULATION DEFECTS

1960 ◽  
Vol 3 (3) ◽  
pp. 703-717 ◽  
Author(s):  
KEITH P. RUSSELL ◽  
JAMES C. CAILLOUETTE ◽  
LAURENCE D. LONGO
Keyword(s):  
Coagulation Defects

Anti-hepatitis C virus serology in patients affected with congenital coagulation defects: A comparative study using three second generation ELISA tests

1994 ◽  
Vol 15 (3) ◽  
pp. 303-311 ◽  
Author(s):  
Rossella Paolini ◽  
Piero Marson ◽  
Mariangela Vicarioto ◽  
Giuseppe Ongaro ◽  
Marialisa Viero ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Comparative Study ◽  
Second Generation ◽  
Coagulation Defects

Neonatal rupture of the liver: Use of exchange transfusion to correct associated coagulation defects

1971 ◽  
Vol 6 (1) ◽  
pp. 56-61 ◽  
Author(s):  
Maurice N. Srouji ◽  
Margaret L. Williams ◽  
Joseph H. Werner
Keyword(s):  
Exchange Transfusion ◽  
Coagulation Defects

COAGULATION DEFECTS IN OBSTETRIC ACCIDENTS AND DISORDERS

1955 ◽  
Vol 229 (6) ◽  
pp. 695-703 ◽  
Author(s):  
Carl Bachman ◽  
Franklin L. Payne ◽  
Alfred L. Kennan
Keyword(s):  
Coagulation Defects

scholarly journals Paediatric nonbronchoscopic bronchoalveolar lavage overview and recommendations for clinical practice

2006 ◽  
Vol 62 (1) ◽  
Author(s):  
B. M. Morrow ◽  
M. J. Futter ◽  
A. C. Argent
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Clinical Practice ◽  
Respiratory Tract ◽  
Bronchoalveolar Lavage ◽  
Pulmonary Disease ◽  
Paediatric Intensive Care Unit ◽  
Lower Respiratory Tract ◽  
Paediatric Intensive Care ◽  
Coagulation Defects

NB-BAL is an effective procedure for the diagnosis of pulmonary disease processes in ventilated infants and children. This procedure is, however, not without risks to both patients and staff. Numerous complications of NB-BAL exist, with hypoxia being themost common. As a result, care should be taken in performing NB-BAL on haemodynamically unstable patients; patients with coagulation defects; and patients with cardiac or brain abnormalities.This paper presents an overview of paediatric nonbronchoscopic bronchoalveolar lavage (NB-BAL) including: the rationale for NB-BAL; the complications associated with the procedure; indications and contraindications. It also recommends an evidence-basedclinical guideline for performing the procedure in the paediatric intensive care unit. By following the NB-BAL guidelines presented in this paper, one can ensure that an effective specimen is obtained from the lower respiratory tract, whilst minimising the risk to the patient.

Sign in / Sign up

Export Citation Format

Share Document